109 related articles for article (PubMed ID: 32006351)
1. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
2. Development of a Functional Nanobody Targeting Programmed Cell Death Protein-1 as Immune Checkpoint Inhibitor.
Hosseininejad-Chafi M; Kianmehr Z; Pooshang-Bagheri K; Kazemi-Lomedasht F; Behdani M
Curr Pharm Des; 2023; 29(29):2336-2344. PubMed ID: 37859326
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics.
Richaud AD; Zaghouani M; Zhao G; Wangpaichitr M; Savaraj N; Roche SP
Chembiochem; 2022 Nov; 23(21):e202200449. PubMed ID: 36082509
[TBL] [Abstract][Full Text] [Related]
4. PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems.
Muscatello LV; Gobbo F; Avallone G; Innao M; Benazzi C; D'Annunzio G; Romaniello D; Orioles M; Lauriola M; Sarli G
Vet Pathol; 2024 May; 61(3):393-401. PubMed ID: 37920996
[TBL] [Abstract][Full Text] [Related]
5. What role does PDL1 play in EMT changes in tumors and fibrosis?
Zhang YC; Zhang YT; Wang Y; Zhao Y; He LJ
Front Immunol; 2023; 14():1226038. PubMed ID: 37649487
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic bodies inhibit inflammation by PDL1-PD1-mediated macrophage metabolic reprogramming.
Jiang T; Xia Y; Wang W; Zhao J; Liu W; Liu S; Shi S; Li B; He X; Jin Y
Cell Prolif; 2024 Jan; 57(1):e13531. PubMed ID: 37553821
[TBL] [Abstract][Full Text] [Related]
7. PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx.
Saez-Ibañez AR; Sommers E; Upadhaya S; Campbell J
Nat Rev Drug Discov; 2023 Dec; 22(12):944-945. PubMed ID: 37914811
[No Abstract] [Full Text] [Related]
8. Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours.
Li D; Wang R; Liang T; Ren H; Park C; Tai CH; Ni W; Zhou J; Mackay S; Edmondson E; Khan J; Croix BS; Ho M
Nat Commun; 2023 Sep; 14(1):5920. PubMed ID: 37739951
[TBL] [Abstract][Full Text] [Related]
9. PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation.
Chmiest D; Podavini S; Ioannidou K; Vallois D; Décaillet C; Gonzalez M; Quadroni M; Blackney K; Schairer R; de Leval L; Thome M
Blood Adv; 2024 Jun; 8(11):2908-2923. PubMed ID: 38513140
[TBL] [Abstract][Full Text] [Related]
10. Neuronally expressed PDL1, not PD1, suppresses acute nociception.
Meerschaert KA; Edwards BS; Epouhe AY; Jefferson B; Friedman R; Babyok OL; Moy JK; Kehinde F; Liu C; Workman CJ; Vignali DAA; Albers KM; Koerber HR; Gold MS; Davis BM; Scheff NN; Saloman JL
Brain Behav Immun; 2022 Nov; 106():233-246. PubMed ID: 36089217
[TBL] [Abstract][Full Text] [Related]
11. Truncated PD1 Engineered Gas-Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells.
Zhang S; Liang Y; Ji P; Zheng R; Lu F; Hou G; Yang G; Yuan L
Adv Sci (Weinh); 2024 Mar; 11(12):e2305891. PubMed ID: 38263860
[TBL] [Abstract][Full Text] [Related]
12. A general protocol for the generation of Nanobodies for structural biology.
Pardon E; Laeremans T; Triest S; Rasmussen SG; Wohlkönig A; Ruf A; Muyldermans S; Hol WG; Kobilka BK; Steyaert J
Nat Protoc; 2014 Mar; 9(3):674-93. PubMed ID: 24577359
[TBL] [Abstract][Full Text] [Related]
13. Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus.
Remy C; Pintado E; Dunlop M; Schön S; Kleinpeter P; Rozanes H; Fend L; Brandely R; Geist M; Suhner D; Winter E; Silvestre N; Huguet C; Fitzgerald P; Quéméneur E; Marchand JB
Front Bioeng Biotechnol; 2023; 11():1247802. PubMed ID: 38053848
[TBL] [Abstract][Full Text] [Related]
14. Using NanoB
Shi X; Zhang J
Cell Rep Methods; 2023 Mar; 3(3):100438. PubMed ID: 37056367
[TBL] [Abstract][Full Text] [Related]
15. Generation of mWasabi fluorescent protein-binding nanobodies.
Li S; Shan H; Wang T; Zheng X; Shi M; Chen B; Lu H; Zhang Y; Zhao S; Hua Z
Anal Biochem; 2020 Nov; 608():113875. PubMed ID: 32739350
[TBL] [Abstract][Full Text] [Related]
16. Recombinant expression of nanobodies and nanobody-derived immunoreagents.
de Marco A
Protein Expr Purif; 2020 Aug; 172():105645. PubMed ID: 32289357
[TBL] [Abstract][Full Text] [Related]
17. Annexin A5 is essential for PKCθ translocation during T-cell activation.
Hu Z; Li L; Zhu B; Huang Y; Wang X; Lin X; Li M; Xu P; Zhang X; Zhang J; Hua Z
J Biol Chem; 2020 Oct; 295(41):14214-14221. PubMed ID: 32796034
[TBL] [Abstract][Full Text] [Related]
18. Extracellular signal regulated kinase 5 promotes cell migration, invasion and lung metastasis in a FAK-dependent manner.
Jiang W; Cai F; Xu H; Lu Y; Chen J; Liu J; Cao N; Zhang X; Chen X; Huang Q; Zhuang H; Hua ZC
Protein Cell; 2020 Nov; 11(11):825-845. PubMed ID: 32144580
[TBL] [Abstract][Full Text] [Related]
19. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.
Karami E; Sabatier JM; Behdani M; Irani S; Kazemi-Lomedasht F
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1233-1239. PubMed ID: 32441172
[TBL] [Abstract][Full Text] [Related]
20. Nanobodies in cancer.
Verhaar ER; Woodham AW; Ploegh HL
Semin Immunol; 2021 Feb; 52():101425. PubMed ID: 33272897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
